Opioid Use Disorder Guideline
Algorithm
mOUD Algorithm
Initial Inpatient Management of Opioid Use Disorder in Pregnancy or Labor
Case
A 25-year-old G1P0 at 32 weeks gestation presents to the obstetric ED acutely withdrawing from opioids.
Assessment
What do you need to consider for opioid use disorder?
- Is she actually withdrawing? If so, can we initiate buprenorphine treatment?
- Symptoms of withdrawl: lacrimation or rhinorrhea, piloerection "goose flesh", myalgia, diarrhea, nausea/vomiting, pupillary dilation, photophobia, insomnia, autonomic hyperactivity (tachypnea, hyperreflexia, tachycardia, sweating, hypertension, hyperthermia), and yawning.
- Admit to an inpatient unit
- Obtain a thorough history including what substances, last use, and route of use
- If unable to obtain a history or it is incongruent with presentation, consider urine drug screen (patient consent may be required; highly recommended; check hospital policy)
- Assess vitals, to include COWS score[1]
- COWS > or = 8 AND one objective finding of withdrawal
- Physical exam
- Labs: Urine drug screen (consent), LFTs, STI testing
- Non-Stress Test if ≥ 23-24 weeks
- Assess their intent to continue using opioids versus starting medication assisted therapy (MAT)
- If they want to start MAT, obtain written CONSENT/CONTRACT PRIOR TO INDUCTION
Treatment
If opioids (fentanyl) and want to continue using:
If opioids (fentanyl) and want to continue using:
- Replace their opioid
- hydromorphone 4-8 mg PO q 1-2 hrs PRN
- You will likely need to increase that dose so do not hesitate to go up if necessary (up to 8-12 mg PO q 1 hr PRN)
If opioids (fentanyl) and want to start Medication Assisted Therapy (MAT):
If opioids (fentanyl) and want to start Medication Assisted Therapy (MAT):
- With methadone (time of last use doesn’t matter)
- Get an EKG to evaluate QTs interval (consider buprenorphine if QTC > 500)
- Day 1: methadone 40 mg and in 4 hrs repeat 20 mg PRN x1
- Day 2: methadone 60 mg and in 4 hrs repeat 20 mg PRN x1
- Day 3: methadone 80 mg and in 4 hrs repeat 20 mg PRN x1
- Day 4: methadone 100 mg. Obtain a second EKG for QTc interval
- Opioid replacement during this induction of methadone
- Will need referral to an approved methadone treatment clinic
- With buprenorphine (if less than 24 hours since last use)
- Start with micro-induction:
- Buprenorphine 0.5 mg SL q 4 hrs for 24 hrs
- Then buprenorphine 1 mg SL q 4 hrs x 24 hrs
- Then buprenorphine 2 mg SL q 4 hrs x 24 hrs
- Opioid replacement during this induction of buprenorphine.
- Start with micro-induction:
- Adjunctive medications for withdrawal (usually 4-12 hrs after last use):
- Clonidine 0.1 mg PO q 6 hrs prn
- Gabapentin 300 mg PO q 6 hrs prn
- Cyclobenzaprine 5-10 mg q 8 hrs prn
- Can use Tizanidine 4 mg PO q hrs prn, discuss feeding plans w/patient as it is an L4 med
- Hydroxyzine 25-50 mg PO q 6 hrs prn
Post-operative management in the first 24 hrs
Post-operative management in the first 24 hrs
- Consider continuous epidural x 24 hrs
- Consider TAP block by anesthesia
- Multimodal pain mgmt: APAP, ketorolac, opioids if necessary
If > 24 hours since last use, follow BRIDGE protocol for buprenorphine start. Can use either Suboxone® (Buprenorphine / Naloxone) or Subutex® buprenorphine) in pregnancy.
- Start buprenorphine 8mg sublingual
- Rescore COWS q 1 - 1.5 hours and redose Suboxone 4mg SL q 1 - 1.5 hours: GOAL IS 80% REDUCTION OR SCORE < 5.
TOTAL MAX DOSE OF 12mg ON DAY 1 - NST prior to discharge if ≥ 23-24 weeks
- Rx provided for total dose given on induction day (NOTE ALL SUBOXONE SCRIPTS MUST BE WRITTEN AS q DAY DOSING)
Multidisciplinary team care model
Multidisciplinary team care model
- Team to include social workers, psychiatry, MFM, addiction resources in your area.
- Local outpatient referral centers, suggest biannual review of local resources to keep up to date.
- Example: Nexus Recovery https://nexusrecovery.org/
- Residential, medical, psychiatry, outpatient, childhood development center
- Example: Nexus Recovery https://nexusrecovery.org/
Clinical Considerations
Clinical Considerations
- Avoid Nubain and Stadol (partial antagonist and can put patient in withdrawal)
- Consider use of TAP/QL blocks, enhanced recovery pathways with around the clock Tylenol 1000mg q6 hours/Ibuprofen 600mg q6 hours
- Pain management post cesarean section, shared decision making with patient. Opioid dependent patients require higher doses.
- Discharge home with Narcan, link to goodrx.com for free Narcan kits
- FDA has now approved Narcan nasal spray[2]
Other Considerations for Management
Other Considerations for Management
Links to Useful Clinical Resources
Comprehensive Toolkits
Comprehensive Toolkits
CQMCC (California Maternal Quality Care Collaborative)
OUD Clinical Care Checklist example. CMQCC referencing Illinois
Notable association guidelines
Notable association guidelines
- ACOG
- Opioid Use and Opioid Use Disorder in Pregnancy. Committee Opinion. Number 711. August 2017, reaffirmed 2021. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/08/opioid-use-and-opioid-use- disorder-in-pregnancy
- AIM
- Care for Pregnant and Postpartum People with Substance Abuse Disorder. https://saferbirth.org/wp-content/uploads/R3_AIM_Bundle_CPPPSUD_Resources.pdf
- SAMHSA
- Evidence-based, Whole-Person Care for Pregnant People who Have Opioid Use Disorder. SAMHSA Advisory. March 2024. https://store.samhsa.gov/sites/default/files/whole-person-care-pregnant-pe...
- Washington State Health Association
- Sample Guideline for Opioid Use Disorder in Pregnancy. https://www.wsha.org/perinatal-substance-use-disorder-learning-collaborative/
References
- Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-9. [PMID:12924748]
- Commissioner, Office of the. “FDA Approves First Over-the-Counter Naloxone Nasal Spray.” FDA. FDA, March 29, 2023.
Last updated: August 12, 2024
Citation
"Opioid Use Disorder Guideline." Clinical Consults and Guidelines, 2024. SOGH Resource Center, www.unboundmedicine.com/sogh/view/Clinical Consults and Guidelines/3357001/all/Opioid_Use_Disorder_Guideline.
Opioid Use Disorder Guideline. Clinical Consults and Guidelines. 2024. https://www.unboundmedicine.com/sogh/view/Clinical Consults and Guidelines/3357001/all/Opioid_Use_Disorder_Guideline. Accessed May 3, 2026.
Opioid Use Disorder Guideline. (2024). In Clinical Consults and Guidelines https://www.unboundmedicine.com/sogh/view/Clinical Consults and Guidelines/3357001/all/Opioid_Use_Disorder_Guideline
Opioid Use Disorder Guideline [Internet]. In: Clinical Consults and Guidelines. ; 2024. [cited 2026 May 03]. Available from: https://www.unboundmedicine.com/sogh/view/Clinical Consults and Guidelines/3357001/all/Opioid_Use_Disorder_Guideline.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Opioid Use Disorder Guideline
ID - 3357001
Y1 - 2024/08/12/
BT - Clinical Consults and Guidelines
UR - https://www.unboundmedicine.com/sogh/view/Clinical Consults and Guidelines/3357001/all/Opioid_Use_Disorder_Guideline
DB - SOGH Resource Center
DP - Unbound Medicine
ER -
Clinical Consults and Guidelines

